News | August 18, 2025
Kwality Pharma receives product registration of Bleomycin 15 IU per vial in Mexico
The projected business potential is around US$ 1 million in the first year
The projected business potential is around US$ 1 million in the first year
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
_256_384.jpg)
Marksans Pharma gets USFDA nod for acid reflux drug
Glenmark USA is named in multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S
Reinforcing commitment to ethical and sustainable growth
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), KENGREAL of Chiesi USA
SMS Pharmaceuticals has reported total income of Rs. 196.64 crores during the period ended June 30, 2025
Subscribe To Our Newsletter & Stay Updated
